A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1900 participants.
Also called NCT01157455
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,900 participants
- Sponsor
- CCRF Consulting Co., Ltd.
- Registry
-
NCT01157455
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01157455. Allocation not applicable; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization
- Acronym
- SEEDS
- Condition
- Coronary Artery Diseases
- Intervention (Procedure)
- Everolimus Drug Eluting Stent
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Heparin or Bivalirudin
- Lead sponsor
- CCRF Consulting Co., Ltd.
Record details
- Record id
cardio:ct-nct01157455- Content hash
c3494bf8ab7a65b8b479d56d29200adcd5863fbe69b1969ea1623349b6684775